Advances in non-intensive chemotherapy treatment options for adults diagnosed with acute myeloid leukemia

Leukemia Research
Elizabeth A GriffithsThomas Prebet

Abstract

Acute myeloid leukemia (AML) is primarily a disease of older adults. Many older patients with AML are not candidates for intensive chemotherapy regimens aimed at inducing remission before transplantation. The prognosis for this patient population remains poor, with 5-year overall survival (OS) rates of less than 10 %. At present, there is no standard of care, and clinical trials should be considered. Hypomethylating agents often are the mainstay of treatment in this setting; however, improved genetic profiling and risk stratification based on molecular, biological, and clinical characteristics of AML enhance the ability to identify an individual patient's risk and can refine therapeutic options. Over the past 2 years, several novel agents have been approved for AML patients in either the frontline or relapsed settings. Additional agents have also shown promising activity. It is becoming a challenge for physicians to navigate these different options and select the optimal therapy or combination of therapies. The aim of this review is to summarize the available information to assist with treatment decisions for leukemia patients who are not suitable for intensive chemotherapy.

References

May 27, 2004·JAMA : the Journal of the American Medical Association·Jay F PiccirilloEdward L Spitznagel
Sep 25, 2008·Journal of the American Geriatrics Society·Fabio SalviPaolo Dessì-Fulgheri
Dec 23, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Amanda F CashenJohn F DiPersio
Dec 23, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pierre FenauxLewis R Silverman
Sep 5, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jorge E CortesMark Levis
Dec 18, 2014·Blood·Gert Ossenkoppele, Bob Löwenberg
Mar 18, 2015·Clinical Lymphoma, Myeloma & Leukemia·Brenda W CooperHillard M Lazarus
Mar 31, 2015·The Journal of Clinical Investigation·Kristen MeldiMaria E Figueroa
Apr 11, 2015·American Journal of Hematology·Tapan M KadiaHagop Kantarjian
Jan 1, 2014·Journal of Clinical Medicine·Marjan CruijsenGerwin Huls
Aug 25, 2015·Clinical Lymphoma, Myeloma & Leukemia·Monica R MuppidiEunice S Wang
Oct 11, 2016·Leukemia·B C MedeirosR Swords
Dec 14, 2016·The New England Journal of Medicine·John S WelchTimothy J Ley
Jan 6, 2017·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Feb 22, 2017·Journal of Hematology & Oncology·Hubert HacklRotraud Wieser
Apr 20, 2017·Journal of Hematology & Oncology·Caner Saygin, Hetty E Carraway
Jun 8, 2017·Blood·Eytan M SteinMartin S Tallman
Jun 24, 2017·The New England Journal of Medicine·Richard M StoneHartmut Döhner

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.